Stockscreener 앱 받기
14.77
1.72%
0.25
시장 영업 전:
15.16
0.39
+2.64%
전일 마감가:
$14.52
열려 있는:
$14.5
하루 거래량:
464.06K
Relative Volume:
0.70
시가총액:
$1.37B
수익:
-
순이익/손실:
$-56.88M
주가수익비율:
-22.37
EPS:
-0.6604
순현금흐름:
$-39.43M
1주 성능:
-4.65%
1개월 성능:
+0.48%
6개월 성능:
+110.70%
1년 성능:
+263.79%
1일 변동 폭
$14.31
$14.80
1주일 범위
$14.31
$15.62
52주 변동 폭
$3.43
$15.79
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
14.77 | 1.37B | 0 | -56.88M | -39.43M | -0.6604 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-04-24 | 개시 | H.C. Wainwright | Buy |
| 2022-04-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-04-08 | 개시 | Piper Sandler | Overweight |
| 2022-04-04 | 개시 | Citigroup | Buy |
모두보기
Alpha Tau Medical Ltd 주식(DRTS)의 최신 뉴스
Alpha Tau Medical Ltd Balance Sheet – FWB:H44 - TradingView
Debt to assets ratio of Alpha Tau Medical Ltd – FWB:H44 - TradingView
Net income of Alpha Tau Medical Ltd – FWB:H44 - TradingView
Alpha Tau Medical stock trades at USD 15.30 - AD HOC NEWS
Alpha Tau Medical (DRTS) Reports Early Trial Progress, Is The Premium Already Priced In? - simplywall.st
Alpha Tau Medical Ltd.(NasdaqCM: DRTS) added to S&P Global BMI Index - marketscreener.com
Alpha Tau Medical stock holds steady as investors await next results - AD HOC NEWS
How Early Cancer Trial Results Will Impact Alpha Tau Medical Stock (DRTS) - simplywall.st
Alpha Tau Medical Ltd stock hits 52-week high at 15.2 USD - Investing.com Australia
Alpha Tau’s Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next. By FinanceWire - Investing.com
Alpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next. - Benzinga
DRTS Stock Gets A Pre-Market Boost – Retail Shrug Off Wider Q1 Loss Ahead Of Key Pancreatic Cancer Data Reveal This Week - Stocktwits
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Is Trial Enrollment Completion Altering The Investment Case For Alpha Tau Medical (DRTS)? - simplywall.st
Is IMPACT Pilot Enrollment Completion Reshaping The Investment Case For Alpha Tau Medical (DRTS)? - simplywall.st
Alpha Tau Medical stock hits 52-week high at 15.11 USD By Investing.com - Investing.com Australia
Alpha Tau Medical stock hits 52-week high at 15.11 USD - Investing.com
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough - Seeking Alpha
Alpha Tau Medical Ltd. Warrant (DRTSW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Alpha Tau to Participate in September Investor Conferences - Alpha Tau Medical
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment - Investing.com Nigeria
Alpha Tau Medical (DRTS) finishes pancreatic IMPACT study signup - Stock Titan
Alpha Tau’s pancreatic cancer study grows from 12 to 48 patients as enrollment closes - Stock Titan
Alpha Tau Medical Ltd. Warrant (DRTSW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Alpha Tau Medical Warrant (DRTSW) Rises 4.1% to $4.05 as Support HoldsStock Picks - careplusvn.com
Alpha Tau Medical (DRTS) officer schedules next stock sale under 10b5-1 plan - Stock Titan
Alpha Tau Medical (NASDAQ:DRTS) Sets New 1-Year HighHere's What Happened - MarketBeat
Alpha Tau Medical stock hits 52-week high at 14.79 USD - Investing.com
Alpha Tau’s Clinical Momentum Put Its Cancer Tech On The Map - Finimize
Price to sales forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Price to earnings forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Price to earnings forward of Alpha Tau Medical Ltd. – BOATS:DRTSW - TradingView
DRTS Stock Price, Quote & Chart - ChartMill
Is Alpha Tau Medical’s (DRTS) Steepening Loss Curve Reframing Its High-Risk Innovation Strategy? - simplywall.st
Alpha Tau Medical Ltd.: Fundamental Analysis and Financial Ratings | DRTS | IL0011839383 - marketscreener.com
Alpha Tau Medical (XTAE:DRTS) Cyclically Adjusted Price-to-FCF : (As of Aug. 15, 2026) - GuruFocus
Alpha Tau Medical (XTAE:DRTS) Shiller PE Ratio : (As of Aug. 21, 2026) - GuruFocus
DRTS Forecast — Price Target — Prediction for 2027 - tradingview.com
Q3 EPS Estimate for Alpha Tau Medical Decreased by Analyst - MarketBeat
Alpha Tau Medical Warrant (DRTSW) Surges 8.96% to $3.89 as Traders Target Key ResistanceTrend Continuation Trade - careplusvn.com
Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 5.4% Following Insider Selling - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $248,220.00 in Stock - MarketBeat
H.C. Wainwright raises Alpha Tau Medical stock price target to $16 - Investing.com
Five Takeaways from AHNS 2026: Alpha DaRT in Combination with Immunotherapy for Advanced Head and Neck Cancer - Alpha Tau Medical
Alpha Tau Medical Ltd (DRTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.87%
자본화:
|
볼륨(24시간):